Clinical Trials Browser

Phase 2 × empagliflozin × 90 days × Clear all

NCT06844669 2026-03-03

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Phase 2 Active not recruiting

Breast Neoplasms, Heart Failure, Cardiotoxicity